We are live on ! Find out more
PA

PharVision Advisers Portfolio holdings

AUM $5.3M
1-Year Est. Return 7.8%
This Fund
S&P 500
This Quarter Est. Return
+6.82%
1 Year Est. Return
+7.8%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$5.3M
AUM Growth
-$4.55M
Cap. Flow
-$4.51M
Cap. Flow %
-84.95%
Top 10 Hldgs %
23.9%
Holding
139
New
42
Increased
4
Reduced
16
Closed
77

Top Sells

Rank Stock Value
1
HPQ icon
HP
HPQ
+$233K
2
FSM icon
Fortuna Silver Mines
FSM
+$183K
3
HLF icon
Herbalife
HLF
+$176K
4
SWBI icon
Smith & Wesson
SWBI
+$176K
5
EFC
Ellington Financial
EFC
+$169K

Sector Composition

Rank Sector Weight
1 Real Estate 14.73%
2 Consumer Discretionary 13.61%
3 Healthcare 11.26%
4 Industrials 10.61%
5 Materials 9.69%

No holdings matched the selected filter criteria.

Similar funds

PharVision Advisers's Q2 2026 Portfolio in Review

As of Q2 2026, PharVision Advisers held 139 positions worth $5.3M, down 46% from $9.86M the previous quarter. Its ten largest holdings account for 24% of the portfolio.

PharVision Advisers withdrew a net $4.51M in Q2 2026, closing 77 positions and reducing 16 holdings. Its most notable exit was HP, an estimated $233K position sold in full.

By sector, the portfolio is most concentrated in Real Estate at 15% of assets, up from 9.6% a quarter earlier, followed by Consumer Discretionary and Healthcare.

Against the trend, PharVision Advisers opened a new position in BitGo Holdings worth $91.8K.

  • PharVision Advisers's largest Q2 2026 buy was BitGo Holdings: 17,722 shares worth $91.8K.
  • PharVision Advisers added most to Ultrapar in Q2 2026, an estimated $33.9K increase.
  • PharVision Advisers's biggest Q2 2026 reduction was Melco Resorts & Entertainment, cutting an estimated $109K.
  • PharVision Advisers fully exited HP in Q2 2026, selling an estimated $233K.
  • PharVision Advisers's ten largest holdings make up 24% of its $5.3M portfolio in Q2 2026.
  • PharVision Advisers opened 42 new positions and closed 77 in Q2 2026.
  • PharVision Advisers's portfolio value fell 46% quarter-over-quarter to $5.3M.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.